ArticleScientific reports2025
Predictive factors for the development of macular neovascularization in chronic central serous chorioretinopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Utility of artificial intelligence for the diagnosis, prognosis, and management of central serous chorioretinopathy: a narrative review.International journal of retina and vitreous · 2026Review
- TheOphthalmology science · 2026Article
- Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This single-center, retrospective study analyzed the development of macular neovascularization (MNV) in patients with chronic central serous chorioretinopathy (CSCR) during a treatment-free follow-up period and the factors associated with its development. In total, 236 patients (280 eyes, 149 males and 87 females, mean age 55.3 ± 13.9 years) with treatment-naïve CSCR with no MNV detected on multimodal imaging who were observed for > 6 months were assessed. The association between age, sex, the presence of MNV, central choroidal thickness (CCT), the presence of the double-layer sign (DLS), and the cumulative duration of the persistence of serous retinal detachment (SRD) was also analyzed to determine the visual outcome before the onset of MNV. Twenty-eight (10%) eyes developed MNV over a mean follow-up period of 48.3 ± 43.3 months. The persistence of SRD for ≥ 6 months (p = 0.003) and presence of DLS measuring ≥ 1000 μm in length and < 100 μm in height (p = 0.040) exhibited significant associations with the development of MNV. Furthermore, the persistence of SRD for ≥ 6 months showed a significant association with logMAR visual acuity loss of ≥ 0.3 (p = 0.0009). Thus, the persistence of SRD for ≥ 6 months and numerically defined DLS were identified as predictors for the development of MNV in patients with CSCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.